{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T08:19:50Z","timestamp":1772007590147,"version":"3.50.1"},"reference-count":68,"publisher":"Impact Journals, LLC","issue":"19","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,5,9]]},"DOI":"10.18632\/oncotarget.15649","type":"journal-article","created":{"date-parts":[[2017,2,23]],"date-time":"2017-02-23T15:12:25Z","timestamp":1487862745000},"page":"31478-31493","source":"Crossref","is-referenced-by-count":17,"title":["Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur<i>in vitro<\/i>and<i>in vivo<\/i>and proceed through multiple mechanisms"],"prefix":"10.18632","volume":"8","author":[{"given":"Tri","family":"Nguyen","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Internal Medicine, Virginia Commonwealth University and the Massey Cancer Center, Richmond, VA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Parker","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Internal Medicine, Virginia Commonwealth University and the Massey Cancer Center, Richmond, VA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Hawkins","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Internal Medicine, Virginia Commonwealth University and the Massey Cancer Center, Richmond, VA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beata","family":"Holkova","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Internal Medicine, Virginia Commonwealth University and the Massey Cancer Center, Richmond, VA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor","family":"Yazbeck","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Internal Medicine, Virginia Commonwealth University and the Massey Cancer Center, Richmond, VA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akhil","family":"Kolluri","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Internal Medicine, Virginia Commonwealth University and the Massey Cancer Center, Richmond, VA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maciej","family":"Kmieciak","sequence":"additional","affiliation":[{"name":"Massey Cancer Center, Virginia Commonwealth University Health Sciences Center, Richmond, VA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Rahmani","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Internal Medicine, Virginia Commonwealth University and the Massey Cancer Center, Richmond, VA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Grant","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Internal Medicine, Virginia Commonwealth University and the Massey Cancer Center, Richmond, VA, USA"},{"name":"Departments of Biochemistry, Virginia Commonwealth University, Richmond, VA, USA"},{"name":"Departments of Pharmacology, Virginia Commonwealth University, Richmond, VA, USA"},{"name":"Virginia Institute for Molecular Medicine, Virginia Commonwealth University, Richmond, VA, USA"},{"name":"Massey Cancer Center, Virginia Commonwealth University Health Sciences Center, Richmond, VA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2017,2,23]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S0140-6736(12)60605-9","article-title":"Non-Hodgkin lymphoma","volume":"380","author":"Hancock","year":"2012","journal-title":"Lancet"},{"key":"2","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1182\/blood-2013-01-480392","article-title":"MYC, BCL2, BCL6 in DLBCL: impact for clinics in the future?","volume":"121","author":"Briere","year":"2013","journal-title":"Blood"},{"key":"3","first-page":"922","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Kenkre","year":"2015","journal-title":"NatMed"},{"key":"4","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Radford","year":"2013","journal-title":"NEnglJ Med"},{"key":"5","first-page":"265","article-title":"Polo-like kinases: conservation and divergence in their functions and regulation","volume":"10","author":"Glover","year":"2009","journal-title":"NatRevMolCell Biol"},{"key":"6","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/nrm3819","article-title":"Polo-like kinases: structural variations lead to multiple functions","volume":"15","author":"Bettencourt-Dias","year":"2014","journal-title":"Nature reviews Molecular cell biology"},{"key":"7","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2007-08-104950","article-title":"Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein","volume":"112","author":"Peters","year":"2008","journal-title":"Blood"},{"key":"8","first-page":"371","article-title":"Plk1 and CK2 act in concert to regulate Rad51 during DNA double strand break repair","volume":"45","author":"Esashi","year":"2012","journal-title":"MolCell"},{"key":"9","first-page":"648","article-title":"Polo-like kinases and DNA damage checkpoint: beyond the traditional mitotic functions","volume":"236","author":"Bahassi","year":"2011","journal-title":"ExpBiolMed(Maywood)"},{"key":"10","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.canlet.2014.12.023","article-title":"Polo-like kinase 1 inhibitor BI2536 causes mitotic catastrophe following activation of the spindle assembly checkpoint in non-small cell lung cancer cells","volume":"357","author":"Kim","year":"2015","journal-title":"Cancer Lett"},{"key":"11","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1038\/labinvest.2012.114","article-title":"Dissecting the phenotypes of Plk1 inhibition in cancer cells using novel kinase inhibitory chemical CBB2001","volume":"92","author":"Zhang","year":"2012","journal-title":"Laboratory investigation"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Raab, Kramer, Hehlgans, Sanhaji, Kurunci-Csacsko, Dotsch, Bug, Ottmann, Becker, Pachl, Kuster, Strebhardt. Mitotic arrest and slippage induced by pharmacological inhibition of Polo-like kinase 1. MolOncol. 2014.","DOI":"10.1016\/j.molonc.2014.07.020"},{"key":"13","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1182\/blood-2008-12-195867","article-title":"Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells","volume":"114","author":"Manenti","year":"2009","journal-title":"Blood"},{"key":"14","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/sj.onc.1208272","article-title":"Polo-like kinases (Plks) and cancer","volume":"24","author":"Miyakawa","year":"2005","journal-title":"Oncogene"},{"key":"15","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1158\/1078-0432.CCR-09-1380","article-title":"Targeting Polo-like kinase in cancer therapy","volume":"16","author":"Lampkin","year":"2010","journal-title":"Clin Cancer Res"},{"key":"16","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/sj.bjc.6601610","article-title":"Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma","volume":"90","author":"Hauptmann","year":"2004","journal-title":"British journal of cancer"},{"key":"17","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/pros.20050","article-title":"Polo-like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades","volume":"60","author":"Kristiansen","year":"2004","journal-title":"The Prostate"},{"key":"18","first-page":"225","article-title":"Expression of Polo-Like Kinase (PLK1) in non-Hodgkin\u2019s lymphomas","volume":"46","author":"Yokoyama","year":"2005","journal-title":"LeukLymphoma"},{"key":"19","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1128\/MCB.26.6.2093-2108.2006","article-title":"Normal cells, but not cancer cells, survive severe Plk1 depletion","volume":"26","author":"Erikson","year":"2006","journal-title":"Mol Cell Biol"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Shi, Lasky, Shinde, Stringer, Qian, Liao, Liu, Driscoll, Nestor, Amidon, Rao, Duffey, Manfredi, et al. MLN0905, A Small Molecule PLK1 Inhibitor, Induces Anti-Tumor Responses in Human Models of Diffuse Large B-cell Lymphoma. MolCancer Ther. 2012.","DOI":"10.1158\/1535-7163.MCT-11-1036"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Vose, Friedberg, Waller, Cheson, Juvvigunta, Fritsch, Petit, Munzert, Younes. The Plk1 inhibitor BI 2536 in patients with refractory or relapsed non-Hodgkin lymphoma: a phase I, open-label, single dose-escalation study. LeukLymphoma. 2012.","DOI":"10.3109\/10428194.2012.729833"},{"key":"22","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1158\/1078-0432.CCR-08-2445","article-title":"BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity","volume":"15","author":"Adolf","year":"2009","journal-title":"ClinCancer Res"},{"key":"23","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/med.21392","article-title":"Spotlight on Volasertib: Preclinical and Clinical Evaluation of a Promising Plk1 Inhibitor","volume":"36","author":"Wouters","year":"2016","journal-title":"Medicinal research reviews"},{"key":"24","first-page":"30","article-title":"New and emerging HDAC inhibitors for cancer treatment","volume":"124","author":"Johnstone","year":"2014","journal-title":"JClinInvest"},{"key":"25","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1038\/sj.leu.2404760","article-title":"Apoptosis induced by histone deacetylase inhibitors in leukemic cells is mediated by Bim and Noxa","volume":"21","author":"Cohen","year":"2007","journal-title":"Leukemia"},{"key":"26","first-page":"77","article-title":"Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells","volume":"11","author":"Gronemeyer","year":"2005","journal-title":"NatMed"},{"key":"27","first-page":"87","article-title":"HDAC inhibitors: roles of DNA damage and repair","volume":"116","author":"Rassool","year":"2012","journal-title":"AdvCancer Res"},{"key":"28","doi-asserted-by":"crossref","first-page":"5541","DOI":"10.1038\/sj.onc.1210620","article-title":"Histone deacetylase inhibitors: molecular mechanisms of action","volume":"26","author":"Marks","year":"2007","journal-title":"Oncogene"},{"key":"29","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/sj.onc.1210779","article-title":"Histone deacetylase inhibitors induce mitotic slippage","volume":"27","author":"Gabrielli","year":"2008","journal-title":"Oncogene"},{"key":"30","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.dnarep.2011.07.003","article-title":"Histone deacetylase inhibitor sodium butyrate enhances cellular radiosensitivity by inhibiting both DNA nonhomologous end joining and homologous recombination","volume":"10","author":"Russev","year":"2011","journal-title":"DNA Repair (Amst)"},{"key":"31","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/MOH.0b013e32834788cf","article-title":"Epigenetics and B-cell lymphoma","volume":"18","author":"Melnick","year":"2011","journal-title":"Current opinion in hematology"},{"key":"32","doi-asserted-by":"crossref","first-page":"471","DOI":"10.4155\/fmc.12.6","article-title":"HDAC inhibitors for the treatment of cutaneous T-cell lymphomas","volume":"4","author":"Duvic","year":"2012","journal-title":"Future medicinal chemistry"},{"key":"33","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.3390\/molecules20033898","article-title":"Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents","volume":"20","author":"Wang","year":"2015","journal-title":"Molecules"},{"key":"34","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1083\/jcb.201205090","article-title":"Polo-like kinase-1 regulates kinetochore-microtubule dynamics and spindle checkpoint silencing","volume":"198","author":"Lampson","year":"2012","journal-title":"JCell Biol"},{"key":"35","first-page":"563","article-title":"Histone deacetylase inhibitors (HDI) cause DNA damage in leukemia cells: a mechanism for leukemia-specific HDI-dependent apoptosis?","volume":"4","author":"Rassool","year":"2006","journal-title":"MolCancer Res"},{"key":"36","doi-asserted-by":"crossref","first-page":"14639","DOI":"10.1073\/pnas.1008522107","article-title":"Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair","volume":"107","author":"Marks","year":"2010","journal-title":"ProcNatlAcadSciUSA"},{"key":"37","first-page":"2179","article-title":"Expression of PLK1 and survivin in diffuse large B-cell lymphoma","volume":"48","author":"Zou","year":"2007","journal-title":"LeukLymphoma"},{"key":"38","doi-asserted-by":"crossref","first-page":"5291","DOI":"10.1158\/1078-0432.CCR-07-0871","article-title":"Bortezomib for the treatment of mantle cell lymphoma","volume":"13","author":"Pazdur","year":"2007","journal-title":"Clin Cancer Res"},{"key":"39","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1412096","article-title":"Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma","volume":"372","author":"Drach","year":"2015","journal-title":"The New England journal of medicine"},{"key":"40","first-page":"5432","article-title":"Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma","volume":"116","author":"Leonard","year":"2011","journal-title":"Cancer"},{"key":"41","first-page":"690","article-title":"Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma","volume":"29","author":"Coleman","year":"2011","journal-title":"JClinOncol"},{"key":"42","first-page":"e1435","article-title":"Histone deacetylase inhibitors promote glioma cell death by G2 checkpoint abrogation leading to mitotic catastrophe","volume":"5","author":"Llovera","year":"2014","journal-title":"Cell DeathDis"},{"key":"43","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1038\/jid.2009.172","article-title":"Targeted depletion of Polo-like kinase (Plk) 1 through lentiviral shRNA or a small-molecule inhibitor causes mitotic catastrophe and induction of apoptosis in human melanoma cells","volume":"129","author":"Ahmad","year":"2009","journal-title":"The Journal of investigative dermatology"},{"key":"44","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/j.1365-2141.2010.08159.x","article-title":"Advances in the understanding of MYC-induced lymphomagenesis","volume":"149","author":"Wirth","year":"2010","journal-title":"British journal of haematology"},{"key":"45","first-page":"814","article-title":"Polo-like kinase 1 (Plk1) in cutaneous T-cell lymphoma","volume":"164","author":"Wood","year":"2011","journal-title":"BrJDermatol"},{"key":"46","doi-asserted-by":"crossref","first-page":"708","DOI":"10.3109\/10428194.2012.729833","article-title":"The Plk1 inhibitor BI 2536 in patients with refractory or relapsed non-Hodgkin lymphoma: a phase I, open-label, single dose-escalation study","volume":"54","author":"Younes","year":"2013","journal-title":"Leukemia & lymphoma"},{"key":"47","first-page":"515","article-title":"Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors","volume":"147","author":"Younes","year":"2009","journal-title":"BrJHaematol"},{"key":"48","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1158\/1078-0432.CCR-14-3119","article-title":"FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma","volume":"21","author":"Dorff","year":"2015","journal-title":"ClinCancer Res"},{"key":"49","doi-asserted-by":"crossref","first-page":"4279","DOI":"10.1096\/fj.12-222893","article-title":"Targeting prostate cancer cell lines with polo-like kinase 1 inhibitors as a single agent and in combination with histone deacetylase inhibitors","volume":"27","author":"Kachhap","year":"2013","journal-title":"FASEB journal"},{"key":"50","first-page":"107","article-title":"DNA damage tolerance: a double-edged sword guarding the genome","volume":"2","author":"Chen","year":"2013","journal-title":"Translational cancer research"},{"key":"51","doi-asserted-by":"crossref","first-page":"5318","DOI":"10.1158\/0008-5472.CAN-06-3996","article-title":"Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation","volume":"67","author":"Chen","year":"2007","journal-title":"Cancer Res"},{"key":"52","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1091\/mbc.11.6.2069","article-title":"Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells","volume":"11","author":"Gabrielli","year":"2000","journal-title":"Molecular biology of the cell"},{"key":"53","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1182\/blood-2012-06-435842","article-title":"MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma","volume":"121","author":"Cogliatti","year":"2013","journal-title":"Blood"},{"key":"54","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1073\/pnas.0500369102","article-title":"Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors","volume":"102","author":"Johnstone","year":"2005","journal-title":"ProcNatlAcadSciUSA"},{"key":"55","first-page":"305","article-title":"Dual kinase-bromodomain inhibitors for rationally designed polypharmacology","volume":"10","author":"Knapp","year":"2014","journal-title":"NatChemBiol"},{"key":"56","doi-asserted-by":"publisher","first-page":"17698","DOI":"10.18632\/oncotarget.4131","article-title":"BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells","volume":"6","author":"Dombret","year":"2015","journal-title":"Oncotarget"},{"key":"57","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.18632\/oncotarget.4131","article-title":"Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma","volume":"5","author":"Vibhakar","year":"2014","journal-title":"Oncotarget"},{"key":"58","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccell.2015.06.001","article-title":"MYC Is a Major Determinant of Mitotic Cell Fate","volume":"28","author":"Procter","year":"2015","journal-title":"Cancer Cell"},{"key":"59","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1182\/blood-2005-04-1399","article-title":"Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction","volume":"106","author":"Greiner","year":"2005","journal-title":"Blood"},{"key":"60","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1084\/jem.194.12.1861","article-title":"Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells","volume":"194","author":"Staudt","year":"2001","journal-title":"JExpMed"},{"key":"61","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1200\/JCO.2014.60.2383","article-title":"Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies","volume":"33","author":"Telenius","year":"2015","journal-title":"J Clin Oncol"},{"key":"62","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/his.12884","article-title":"MYC\/BCL6 double-hit lymphoma (DHL): a tumour associated with an aggressive clinical course and poor prognosis","volume":"68","author":"Medeiros","year":"2016","journal-title":"Histopathology"},{"key":"63","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1158\/1535-7163.MCT-13-0714","article-title":"Dinaciclib (SCH727965) inhibits the unfolded protein response through a CDK1- and 5-dependent mechanism","volume":"13","author":"Grant","year":"2014","journal-title":"Molecular cancer therapeutics"},{"key":"64","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1158\/1535-7163.MCT-13-0714","article-title":"Dinaciclib (SCH727965) inhibits the unfolded protein response through a","volume":"13","author":"Grant","year":"2014","journal-title":"MolCancer Ther"},{"key":"65","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1038\/leu.2010.137","article-title":"Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress","volume":"24","author":"Ueda","year":"2010","journal-title":"Leukemia"},{"key":"66","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1158\/1078-0432.CCR-11-0234","article-title":"HDAC inhibitors potentiate the activity of the BCR\/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR\/ABL+ leukemia cellsand","volume":"17","author":"Grant","year":"2011","journal-title":"ClinCancer Res"},{"key":"67","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.otohns.2010.05.007","article-title":"A practical guide to understanding Kaplan-Meier curves","volume":"143","author":"Wang","year":"2010","journal-title":"Otolaryngology--head and neck surgery: official journal of American Academy of Otolaryngology-Head and Neck Surgery"},{"key":"68","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/978-1-61779-080-5_34","article-title":"Analysis of drug interactions","volume":"731","author":"Peters","year":"2011","journal-title":"Methods in molecular biology"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.15649","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T16:40:15Z","timestamp":1750005615000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.15649"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,23]]},"references-count":68,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2017,5,9]]}},"alternative-id":["15649","28416758"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.15649","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,23]]}}}